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Abstract
Background: Current guidelines favor fistulas over catheters as vascular access. Yet, the observational literature
comparing fistulas to catheters has important limitations and biases that may be difficult to overcome in the
absence of randomization. However, it is not clear if physicians would be willing to participate in a clinical trial
comparing fistulas to catheters.
Objectives: We also sought to elicit participants’ opinions on willingness to participate in a future trial regarding
catheters and fistulas.
Design: We created a three-part survey consisting of 19 questions. We collected demographic information,
respondents’ knowledge of the vascular access literature, appropriateness of current guideline recommendations,
and their willingness to participate in a future trial.
Setting: Participants were recruited from Canada, Europe, Australia, and New Zealand.
Participants: Participants include physicians and trainees who are involved in the care of end-stage renal disease
patients requiring vascular access.
Measurements: Descriptive statistics were used to describe baseline characteristics of respondents according to
geographic location. We used logistic regression to model willingness to participate in a future trial.
Methods: We surveyed nephrologists from Canada, Europe, Australia, and New Zealand to assess their willingness
to participate in a randomized trial comparing fistulas to catheters in incident hemodialysis patients.
Results: Our results show that in Canada, 86 % of respondents were willing to participate in a trial (32 % in all
patients; 54 % only in patients at high risk of primary failure). In Europe and Australia/New Zealand, the willingness
to participate in a trial that included all patients was lower (28 % in Europe; 25 % in Australia/New Zealand), as was
a trial that included patients at high risk of primary failure (38 % in Europe; 39 % in Australia/New Zealand).
Nephrologists who have been in practice for a few years, saw a larger volume of patients, or self-identified as
experts in vascular access literature were more likely to participate in a trial.
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Limitations: Survey distribution was limited to vascular access experts in participating European countries and
ultimately led to a discrepancy in numbers of European to non-European respondents overall. Canadian views are
likely over-represented in the overall outcomes.
Conclusions: Our survey results suggest that nephrologists believe there is equipoise surrounding the optimal
vascular access strategy and that a randomized controlled study should be undertaken, but restricted to those
individuals with a high risk of primary fistula failure.
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Abrégé
Mise en contexte: À l’heure actuelle, les lignes directrices en matière d’accès vasculaire préconisent l’usage d’une
fistule plutôt que d’un cathéter. Or, en consultant la littérature faisant état des études observationnelles comparant
l’usage de ces deux types d’accès vasculaire, on note des limites ou un parti-pris qui sont difficilement évitables en
absence de randomisation. Néanmoins, il demeure difficile de prévoir si les médecins traitants seraient enclins à
participer à des essais cliniques comparatifs de ces deux méthodes.
Objectifs de l’étude: Cette étude avait pour objectif de sonder l’intérêt des participants à prendre part à un essai
clinique comparant l’usage des cathéters et des fistules.
Paramètres de l’étude: Pour atteindre cet objectif, nous avons créé un sondage en trois parties constitué de 19
questions. Nous avons colligé les renseignements démographiques des participants, évalué leur connaissance de la
littérature et des recommandations actuelles au sujet des accès vasculaires, en plus de sonder leur intérêt à prendre
part à un essai clinique à venir.
Cadre de l’étude: Les participants ont été recrutés au Canada, en Europe, en Australie et en Nouvelle-Zélande.
Participants: Des médecins traitants ainsi que des stagiaires en néphrologie, impliqués auprès de patients atteints
d’insuffisance rénale terminale et requérant la mise en place d’un accès vasculaire, ont pris part à cette enquête.
Mesures: Des statistiques descriptives ont été utilisées pour définir les caractéristiques démographiques initiales des
répondants selon leur situation géographique. Un modèle de régression logistique a été utilisé pour évaluer leur
intérêt à participer à un essai clinique.
Méthodologie: Des néphrologues canadiens, australiens, néo-zélandais ou provenant de plusieurs pays d’Europe
ont été sondés sur leur intérêt à participer à un essai clinique randomisé comparant l’usage d’une fistule ou d’un
cathéter comme accès vasculaire chez les patients nouvellement dialysés.
Résultats: Le sondage a démontré qu’au Canada, 86 % des répondants seraient enclins à prendre part à un essai
clinique ; 32 % y feraient participer tous leurs patients sous dialyse alors que 54 % ne le feraient que pour ceux
présentant un risque élevé de défaillance primaire de la fistule. Pour le reste des participants, l’intérêt en regard
d’un essai clinique ouvert à tous les patients sous dialyse s’est avéré moindre (28 % en Europe, 25 % en Australie et
Nouvelle-Zélande), tout comme pour l’idée de n’y inclure que les patients présentant un risque élevé de défaillance
primaire de la fistule (38 % pour l’Europe et 39 % pour l’Australie et la Nouvelle-Zélande combinées). Les
néphrologues qui pratiquaient depuis plusieurs années, qui suivaient un grand nombre de patients ou qui se
définissaient comme des experts de la littérature sur les accès vasculaires étaient plus enclins à participer à des
essais cliniques à ce sujet.
Limites de l’étude: La distribution du questionnaire était limitée aux experts de la question de l’accès vasculaire en
hémodialyse dans les pays d’Europe participants. Ceci a fait en sorte que le nombre de répondants européens s’est
trouvé en déséquilibre en comparaison du nombre de répondants provenant de l’extérieur de l’Europe. De plus, les
Canadiens étant surreprésentés parmi les répondants, les résultats obtenus expriment davantage leurs vues que
celles des néphrologues provenant d’Australie, de la Nouvelle-Zélande ou des pays d’Europe participants.
Conclusion: Les résultats du sondage suggèrent qu’en général, les néphrologues croient que les deux méthodes se
valent au moment de la mise en place d’un accès vasculaire. La plupart sont également d’avis qu’un essai clinique
contrôlé et randomisé pour les comparer devrait être réalisé, mais plusieurs croient que celui-ci ne devrait inclure
que les patients présentant un risque élevé de défaillance primaire de la fistule.
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What was known before
Fistulas are considered the preferred form of vascular
access and are widely promoted by vascular access ex-
perts and guideline committees. These recommenda-
tions are based on observational data showing an
association between fistula use and improved survival,
lower procedure rates, and lower costs. There has never
been a randomized controlled trial comparing the out-
comes of patients treated with fistulas to those treated
with catheters, and it was not clear if nephrologists
would be willing to participate in a trial.
What this adds
This survey suggests that nephrologists in Canada, Europe,
and Australia/New Zealand would be willing to participate
in a future randomized controlled trial comparing out-
comes of patients treated with fistulas to those treated with
catheters.
Background
The majority of people with kidney failure are treated
with hemodialysis and require access to the bloodstream.
While vascular access (“access”) is a lifeline, it is also a
key driver of morbidity, mortality, and cost [1]. Arterio-
venous fistulas, arteriovenous grafts, and central venous
catheters are the three main options for vascular access,
but the majority of hemodialysis patients use either a fis-
tula or catheter [2]. Guidelines recommend a fistula for
of access based on observational data indicating that use
of fistulas is associated with a lower risk of complica-
tions and access-related costs and longer patient survival
[1, 3–9]. This had led to a number of local, regional, and
national initiatives designed to increase the proportion
of individuals treated with them [10].
The observational literature comparing fistulas to
catheters has important limitations that may have biased
previous comparisons and may be difficult to overcome
in the absence of randomization [11, 12]. Patients who
start dialysis urgently, those who are acutely ill, and
those with the highest burden of comorbidity are treated
almost exclusively with catheters. Studies including these
patients in the catheter group are at high risk of indica-
tion bias. Further, most studies did not ascertain access
outcomes rigorously or did not report them comprehen-
sively. These studies are at high risk of ascertainment
and information bias [13].
The adoption of health-care interventions in the ab-
sence of sufficient evidence of safety and efficacy can
lead to inefficient use of health-care resources and, po-
tentially, unintended harm to patients. For example,
increasing the dose of dialysis delivered to patients was
associated with better outcomes in observational studies,
but subsequent randomized trials have failed to show
benefit [14, 15]. Normalizing hemoglobin levels in
patients with kidney disease using erythropoietin-
stimulating agents was also felt to be desirable until
clinical trials showed that it increased the risk of cardio-
vascular events [16–21]. However, it is not clear if physi-
cians would be willing to participate in a clinical trial
comparing fistulas to catheters given that the observa-
tional data have shown a strong and consistent benefit
of fistulas, there are incentives for dialysis programs to
increase the numbers of patients treated with them in
many jurisdictions, and the proportion of patients
treated with a fistula is considered a quality measure.
We surveyed nephrologists from Canada, Europe,
Australia, and New Zealand to assess their willingness to
participate in a randomized trial comparing fistulas to
catheters in incident hemodialysis patients. We also
sought to elicit physician views about vascular access,
their familiarity with the literature, and their opinions
regarding current guideline recommendations.
Methods
Participants
Physicians and trainees who are involved in the care of
end-stage renal disease patients requiring vascular access
were eligible to complete the survey. To ensure a broad
view of practices, we recruited participants from Canada,
Europe, Australia, and New Zealand. This process was
facilitated through the Canadian Society of Nephrology
(CSN), European Renal Association/European Dialysis
and Transplantation Association (ERA/EDTA), and
Australia and New Zealand Society of Nephrology
(ANZSN). The survey was distributed to all members of
the CSN. In Europe, the survey was distributed to indi-
viduals with an interest or expertise in vascular access
from participating countries, as identified by the ERA/
EDTA. Individuals participating in another survey ad-
ministered by the ERA/EDTA were invited to participate
in our survey. The list of physicians who were willing to
be contacted was provided to us. In Australia and New
Zealand, the survey was distributed to the ANZSN
membership. Two reminder emails were sent to increase
participation in the survey. The numbers of physicians
that the survey was distributed to were not available
from the CSN or the ANZSN.
Survey design
We created a three-part survey consisting of 19 ques-
tions that took approximately 10 min to complete. In
the first part of the survey, we collected demographic
information and information about respondents’ practice
environment, as well as the resources available to them.
In the second section, we asked about the respondents’
knowledge of the vascular access literature and how it
influenced their practices and views. Finally, we asked
respondents to comment on the appropriateness of
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guideline recommendations, whether or not future re-
search was needed in vascular access, and their willing-
ness to participate in a randomized comparison of
fistulas to catheters in hemodialysis patients. A copy of
the Canadian version of the survey is included as an
Additional file 1. The surveys for other jurisdictions did
not differ in content, but references to Canada were re-
placed with Europe and Australia/New Zealand.
Primary outcome
Our primary outcome was the respondents’ willingness to
participate in a randomized trial comparing fistulas to cath-
eters in incident hemodialysis patients. Respondents were
also asked to indicate the population that they felt should
be entered into a clinical trial (all patients, only patients at
high risk of primary fistula failure, or no one, as it was felt
to be unethical) and the essential elements of a trial (e.g.,
minimum follow-up of 3 years, only conducted at sites with
a primary fistula failure rate of less than 50 %).
Statistical analysis
Descriptive statistics were used to describe baseline
characteristics of the survey respondents and their pro-
grams, according to geographic location. We used logis-
tic regression to model willingness to participate in a
randomized trial comparing fistulas to catheters. The
model was adjusted for covariates that, a priori, were felt
likely to be associated with willingness to participate in a
randomized trial based on a review of the literature and
clinical intuition. The model included a geographic
region (Canada, Europe, Australia/New Zealand), prac-
tice setting (urban vs. rural), years in practice (<5, 5–10,
10–15, or >15 years), percentage of time spent in direct
patient care (<25, 26–50, 51–75, and >75 %), presence of
a nephrology fellowship training program at a primary
hospital, risk of primary failure of a fistula at their center
(<25, 26–50, 51–75, and >75 %), and familiarity with the
vascular access literature (expert vs. non-expert).
Ethical approval was not required for this study.
Results
A total of 267 nephrologists and nephrology trainees
participated in the survey. Of those, 248 respondents
fully completed the survey (including the question on
their willingness to participate in a trial). The majority of
respondents were from Canada (68 %), followed by
Australia/New Zealand (21 %) and then Europe (12 %).
As the total number of survey recipients from Canada,
Europe, and Australia/New Zealand was not disclosed,
we were unable to calculate the final response rates.
Participants
The baseline characteristics of the survey respondents, ac-
cording to geographic location, are presented in Table 1.
The respondents were primarily nephrologists (Canada
98 %, Europe 90.6 %, Australia/New Zealand 100 %) who
spent >75 % of their time providing direct patient care
(Canada 40.5 %, Europe 48.3 %, Australia/New Zealand
47.1 %) and who worked in urban hospitals (Canada
93.5 %, Europe 93.1 %, Australia/New Zealand 84.3 %).
Infrastructure and support for vascular access creation
Table 2 shows the support available for vascular access
creation, according to geographic location. There were
significant differences in likelihood of programs having a
vascular access coordinator (p < 0.01) and dedicated vas-
cular access nurses (p < 0.01) among geographic regions,
largely driven by the low numbers of programs in Europe
that had dedicated vascular access staff and clinics.
Willingness to participate in a future RCT
Figure 1 illustrates the respondent’s willingness to par-
ticipate in a randomized controlled trial comparing fis-
tulas to catheters. In total, 79 % of the total respondents
agreed that a future trial was needed. While the majority
of respondents from Europe (66 %) and Australia/New
Zealand (64 %) were supportive of a trial, the proportion
in favor was lower than in Canada (86 %).
Thirty-eight percent of nephrologists who were in
favor of a trial were supportive of a study in all
hemodialysis patients who were candidates for a fistula
(37 % in Canada; 45 % in Europe; 40 % in Australia/New
Zealand), while 62 % of nephrologists indicated that it
should be restricted to individuals at high risk of primary
fistula failure (63 % in Canada; 55 % in Europe; 60 % in
Australia/New Zealand).
Variables associated with willingness to participate in a
clinical trial
Table 3 shows the variables associated with respondents’
willingness to participate in an RCT. The odds ratio of
each variable is adjusted for the potential confounding
effect of all the other variables in the model. In a multi-
variate analysis, participants from Canada were more
likely to indicate that they would be willing to partici-
pate in a trial compared to respondents from Australia/
New Zealand (OR 0.36; 95 % CI 0.16–0.85) or Europe
(OR 0.31; 95 % CI 0.11–0.94). Relative to people who
had been practicing fewer than 5 years, those in practice
for 5–10 years were five times more likely to indicate
willingness to participate (OR 5.07; 95 % CI 1.41–18.26).
Those respondents that spent greater than 75 % of their
time providing direct clinical care were less likely to en-
dorse participation in a trial than those with less than
25 % clinical time (OR 0.86; 95 % CI 0.20–3.63). Partici-
pants who self-identified as vascular access experts
(ORexpert vs. non-expert 2.4; 95 % CI 0.91–6.53), those from
urban settings (ORurban vs. rural 1.39; 95 % CI 0.44–4.45),
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and those who did not know their local risk of primary
fistula failure (ORno knowledge vs. local rate <25% 4.08; 95 %
CI 1.41–11.8) were also more likely to be willing to par-
ticipate in a future trial.
Important elements of a clinical trial
Over half of the participants from all countries felt it
would be important to have a national funding agency
vet the protocol (58 %), while an even greater number
suggested that a data safety and monitoring board
should provide oversight (77 %). A minimum 3-year
follow-up period was felt to be important by the major-
ity of participants (61 %), but participants did not feel
that a trial should be limited to centers with a primary
failure rate of less than 50 % after fistula creation (34 %)
(see Table 4).
Table 1 Baseline characteristics of survey respondents
Canada Europe Australia/NZ
n (%) n (%) n (%)
Age
<35 28 (16.7) 3 (10.3) 10 (19.6)
35–50 93 (55.4) 11 (37.9) 30 (58.8)
51–65 39 (23.2) 15 (51.7) 11 (21.6)
>65 8 (4.8)
Years in practice
<5 37 (22) 3 (10.3) 18 (35.3)
5 to 10 35 (20.8) 5 (17.2) 10 (19.6)
10 to 15 33 (19.6) 3 (10.3) 7 (13.7)
>15 53 (31.5) 18 (62.1) 12 (23.5)
Percentage of time spent in direct patient care
<25 % 11 (6.5) 2 (6.9) 3 (5.9)
25–50 % 28 (16.7) 4 (13.8) 10 (19.6)
51–75 % 61 (36.3) 9 (31) 14 (27.5)
>75 % 68 (40.5) 14 (48.3) 24 (47.1)
Primary hospital affiliation is in urban center 157 (93.5) 27 (93.1) 43 (84.3)
Self-identified vascular access expert 26 (15.5) 16 (55.2) 7 (13.7)
Primary hospital has a nephrology fellowship training program 115 (68.5) 23 (79.3) 45 (88.2)
Risk of primary failure of fistulas at local center
<25 % 52 (31) 20 (69) 30 (58.8)
25–50 % 63 (37.5) 8 (27.6) 8 (15.7)
51–75 % 8 (4.8) - 1 (2)
Do not know 45 (26.8) 1 (3.4) 12 (23.5)
NZ New Zealand
Table 2 Support available for vascular access creation, by geographic location
Canada Europe Australia/NZ p
valuen (%) n (%) n (%)
N = 168 N = 29 N = 51
Vascular access coordinator 149 (88.7) 10 (34.5) 42 (82.4) <0.01
Dedicated vascular access clinica 109 (64.9) 9 (31.0) 27 (52.9) <0.01
Surgeon available at center to create arteriovenous accesses 146 (86.9) 22 (75.9) 46 (90.2) 0.18
Type of operator who create(s) vascular accesses at your center: 0.49
Vascular surgeon 152 (90.5) 25 (86.2) 48 (94.1)
Other (general, urologist, nephrologist, not available) 15 (8.9) 4 (13.8) 3 (5.9)
NZ New Zealand
aStaffed by any combination of physicians, surgeons, and vascular access coordinators/nurses with an interest in vascular access
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Fig. 1 Willingness to participate in a randomized controlled trial comparing fistulas to catheters, by geographic location and patient population. This
figure shows the proportion of survey respondents who were willing to participate in a randomized controlled trial comparing catheters to fistulas in
incident hemodialysis patients, by geographic location, and according to the patient population included. In Canada, 86 % of respondents were
willing to participate in a trial (32 % in all patients; 54 % only in patients at high risk of primary failure). In Europe and Australia/New Zealand, the
willingness to participate in a trial that included all incident hemodialysis patients was lower (28 % Europe; 25 % Australia/New Zealand) as was the
willingness to participate in a trial that included patients at high risk of primary failure of their fistulas (38 % in Europe; 39 % in Australia/New Zealand).
NZ New Zealand
Table 3 Predictors of respondents’ willingness to participate in a randomized controlled trial
Adjusted odds ratio 95 % CI p value
Region
Canada Reference – –
Europe 0.32 0.11–0.91 0.03
Australia/New Zealand 0.37 0.16–0.85 0.02
Number of years licensed and practicing as a nephrologist
5 Reference – –
5 to 10 5.07 1.41–18.26 0.01
10 to 15 1.55 0.54–4.43 0.42
>15 1.20 0.49–2.91 0.69
Percentage of time spent in direct patient care (clinical duties)
<25 % Reference – –
25–50 % 1.55 0.30–8.02 0.60
51–75 % 0.82 0.19–3.59 0.79
>75 % 0.86 0.20–3.63 0.84
Primary hospital affiliation is urban 1.40 0.44–4.45 0.57
Primary hospital has a nephrology fellowship training program? 0.70 0.29–1.70 0.44
Risk of primary failure for arteriovenous fistulas at your center
<25 % Reference – –
25–50 % 1.74 0.78–3.91 0.18
51–75 % 0.56 0.12–2.60 0.46
Do not know 4.08 1.41–11.78 0.01
Self-identified vascular access expert 2.44 0.91–6.53 0.08
CI, confidence interval, OR odds ratio
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Discussion
Our findings confirm that the majority of nephrologists
surveyed from Canada, Europe, and Australia/New Zea-
land would be willing to participate in a randomized trial
comparing fistulas to catheters in incident hemodialysis
patients. However, the majority of respondents felt that it
should be limited to patients who are at high risk of pri-
mary failure of their fistula. Nephrologists from Canada,
those who had been in practice for a short duration of
time, practiced in an urban setting, and self-identified as
vascular access experts were more likely to indicate a will-
ingness to be involved in a trial comparing fistulas to cath-
eters. While fistulas are aggressively promoted, our results
would suggest that many practicing nephrologists feel that
there is sufficient equipoise to warrant a randomized com-
parison of catheters and fistulas.
The majority of nephrologists who were in support of
a randomized trial comparing catheters to fistulas felt
that it should be restricted to individuals with a higher
risk of primary failure. Risk factors for failure to mature
include age over 65, female gender, the presence of per-
ipheral vascular disease and coronary artery disease,
obesity, diabetes, location of the fistula, small-caliber
veins, and ethnicity other than Caucasian [22]. A high
risk of primary failure may alter the risk-benefit ratio in
those undergoing a fistula attempt, as 25–69 % of
fistulas created will fail to mature, depending on the pa-
tient’s risk profile [22]. If a fistula never works, the pa-
tient does not have the opportunity to experience the
potential benefits of avoiding a hemodialysis catheter. In
addition, failure of fistula maturation has previously
been shown to lead to repeated surgical interventions,
disruption of the hemodialysis schedule, and patient dis-
tress [22]. It is also associated with inefficient use of
health-care resources; a trial that tested the benefits of
attempting a fistula in this high-risk patient population
would inform clinical practice and help providers select
the patients most likely to benefit.
Physicians from Canada were more likely to indicate a
willingness to participate in a randomized trial compar-
ing fistulas to catheters. While guideline recommenda-
tions from Canada, Europe, and Australia/New Zealand
consistently recommend fistulas as the preferred form of
vascular access for hemodialysis, the prevalent use of fis-
tulas varies. The DOPPS study showed that the preva-
lence of fistulas in Canada was 50 %, whereas in Europe
the range was 57–83 % [23]. In New Zealand, the rates
were closer to 60 % [24]. This may be due to differences
in the availability of infrastructure or the access to, or
organization of services, although our results would sug-
gest that the infrastructure to support fistula creation
and maintenance are more developed in Canada than in
European centers. It more likely reflects differences in
the attitudes and beliefs of health-care providers.
Interestingly, nephrologists who have practiced for 5–
10 years were more likely to participate in a trial. Those
who were new to practice (<5 years) and those who had
been in practice longer (>10 years) were less likely to be
willing to participate in a clinical trial. The reasons for
this are not clear. New physicians may be more likely to
adhere to the principles taught to them during training,
whereas clinicians who had been in practice for a long
time were more likely ingrained in their practice
patterns and less open to the idea of a clinical trial. Indi-
viduals who spent more of their time in direct patient
care were less likely to want to participate in a trial. The
reasons for this are not clear. It may be that physicians
with a more clinical focus are more likely to adhere to
the teaching they received during their fellowship train-
ing and less likely to read the primary literature for
themselves or to have had additional training in critical
appraisal. This is a potential threat to the feasibility of
an RCT, given that the majority of patients are cared for
by this group of physicians. Finally, self-identified
experts likely have a greater familiarity with the vascular
access literature. As a consequence, they may be more
aware of the limitations of existing studies—that they
are of low quality and prone to bias—and may be more
willing to participate in a clinical trial [4]. However, ex-
perts are more likely to be involved in the generation of
Table 4 Essential elements of a randomized controlled trial
comparing fistulas to catheters in opinion of respondents, by
geographic location
Canada Europe Australia/NZ p value
n (%) n (%) n (%)
N = 168 N = 29 N = 51
Protocol should be
vetted by a national
funding agency
110 (65.5) 11 (37.9) 23 (45.1) <0.01
Data safety and monitoring
board must provide
oversight
139 (82.7) 12 (41.4) 40 (78.4) <0.01
All hemodialysis patients
should be studied
50 (29.8) 10 (34.5) 13 (25.5) 0.69
Only certain high-risk
patient populations,
where the benefit of
fistulas is not clear
based on observational
studies, should be studied
101 (60.1) 14 (48.3) 30 (58.8) 0.49
Only patients who have
failed a previous fistula
attempt should be studied
12 (7.1) 5 (17.2) 7 (13.7) 0.13
Follow-up must be a
minimum of 3 years
105 (62.5) 20 (69) 27 (52.9) 0.31
The study should only
be conducted at centers
with a primary failure
rate of less than 50 %
after fistula creation
63 (37.5) 8 (27.6) 15 (29.4) 0.40
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guideline recommendations, and there appears to be dis-
cordance between the views expressed in our survey and
current guideline recommendations.
Our study has several strengths. First, we recruited re-
spondents from a number of countries in order to explore
geographical differences in opinions. Second, this survey
is the first, to our knowledge, to ask physicians directly
about their willingness to participate in a randomized con-
trolled trial comparing fistulas and catheters. Demonstrat-
ing the presence of equipoise is a necessary step in
justifying an RCT examining this issue. Our results high-
light the discordance between guideline recommendations
that consistently recommend fistulas and the views of ne-
phrologists who responded to our survey. Third, our re-
sults provide insight into the issues felt to be important
considerations in the design of a RCT from the perspec-
tive of the practicing nephrologists. This facilitates devel-
opment of a trial protocol that is feasible and maximizes
the likelihood of participation.
Our study also has limitations. The intent of this sur-
vey was to capture the perception of nephrologists inter-
nationally to inform the development of a future trial.
Outside of Canada, we distributed the survey via the
European Renal Association (ERA) and the Australian
and New Zealand Society for Nephrology. European par-
ticipants were identified by the ERA and were typically
vascular access experts from different countries. This ul-
timately led to a discrepancy in numbers of European to
non-European respondents overall, even though Europe
has a much larger population. It was however, felt that
European respondents’ views were likely reflective of
physician views in their countries of origin, but we are
unable to confirm that. As a consequence, Canadian
views are likely over-represented in the overall out-
comes, but similar results were found for each of the
geographic regions examined. The response rates are not
calculated because we were unable to obtain an accurate
count of the physicians that the survey was distributed
to in any region. In addition, we attempted to engage US
participants in the survey but were unable to do so. As a
consequence, we were unable to gauge physician views
and opinions in the USA, which would have been of
interest. Our results reflect the views of those physicians
who responded to our survey and may not reflect the
views of non-respondents or an individual physician’s ac-
tual practice. Finally, we have only captured the views of
nephrologists. The willingness of patients to be assigned
randomly to different vascular access strategies has not
been explored and is an important consideration. In a
recent study by Manns et al., patients were engaged to
identify their priorities for research in kidney disease
and identified vascular access as a key area of investiga-
tion [25]. Although this does not imply that these pa-
tients would participate in an RCT, it does show the
awareness regarding the importance of further research
in this area from a patient perspective. We are currently
testing the feasibility of enrolling patients in a random-
ized trial that will randomly assign people starting
hemodialysis with a catheter to either attempt fistula
creation or continued use of a tunneled catheter
(NCT02675569).
In summary, the majority of nephrologists we surveyed
from Canada, Europe, Australia, and New Zealand would
be willing to participate in a randomized controlled trial
comparing fistulas to catheters in incident hemodialysis
patients. Our survey results suggest that nephrologists be-
lieve that the existing evidence forming the base of guide-
line recommendations about vascular access is of low
quality, that there is equipoise surrounding the optimal
vascular access strategy for hemodialysis.
Conclusions
The optimal hemodialysis vascular access is not yet
known. The current trend towards fistulas over catheters
is based on observational evidence that is limited in
scope and prone to bias. A randomized control trial
comparing fistulas and catheters would be the most ob-
jective and comprehensive study to prove the superiority
of one form of access over the other. We surveyed ne-
phrologists from Canada, Europe, Australia, and New
Zealand to assess their willingness to participate in the
aforementioned trial. Although the number of Canadian
respondents was greater than those from other regions,
the distribution of responses was similar in all regions.
That is, a majority of our respondents were willing to
participate in a randomized trial but more so if limited
to patients who are at high risk of primary fistula failure.
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